Massimo Mineo served as a C-suite executive in multinational companies and start-ups, spanning drug product development, clinical, regulatory and commercial. He holds an MBA and has gained extensive experience in corporate finance prior to taking on key roles with increasing responsibilities in the pharma industry. In 2008 he served as CEO of Lynapharm SA, in 2010 he became Senior Executive Director of the global international division at Sigma-tau (Alfasigma) and in 2015 he moved to leading Recordati Rare Diseases (Paris) as Managing Director EMEA launching novel drugs for the treatment of metabolic disorders, dermato-oncology and endocrinology, across indications of high unmet medical need. in 2021 he was appointed as CEO at Napo Therapeutics, a clinical stage biotech company developing a novel therapy for GI rare diseases. Massimo is a member of the Italian CEO association (AICEO). He’s passionate and really committed to lead Neurolieve Biosciences bringing innovative therapeutic solutions for ameliorating the quality of life of patients.
